07.02.2017 • NewsElaine BurridgeSolvayBatteries

Solvay Takes DuPont’s Energain Li-Ion Technology

(c) Solvay
(c) Solvay

Belgian chemical group Solvay has acquired DuPont’s Energain lithium-ion high voltage technology for an undisclosed sum. The Brussels-headquartered company said Energain will expand its Special Chem Global Business Unit’s existing portfolio of high-performance salts and additives for electrolytes and strengthen its development capabilities for Li-ion batteries.

Nicolas Cudré-Mauroux, Solvay’s general manager of research & innovation added that the acquisition reinforced the group’s competencies in areas such as modelling and formulations.

The advanced Li-ion battery market is developing rapidly, noted Solvay, driven by increasingly stringent regulations and continuous improvements in performance and cost.

According to a September 2016 report by US-based Transparency Market Research (TMR), a growing shift toward sustainable clean fuels in the automotive sector is a key factor driving the Li-ion battery market. TMR said rising demand for high-power capacity batteries in cars as well as increasing sales of smartphones and other consumer electronics are fuelling growth worldwide. It projects the value of the global Li-ion market to rise from nearly $30 billion in 2015 to more than $77 billion in 2024, showing a compound annual growth rate of 11.6%.

 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.